Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $27.71 Consensus PT from Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been given a consensus recommendation of “Hold” by the twenty-eight research firms that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $27.7083.

Several equities analysts have commented on SRPT shares. Loop Capital set a $25.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Mizuho increased their target price on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Barclays started coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price on the stock. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings raised shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, May 8th.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $17.12 on Friday. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $44.14. The business has a fifty day simple moving average of $20.02 and a 200 day simple moving average of $20.00. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -17.83, a P/E/G ratio of 0.19 and a beta of 0.26.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $2.18. The business had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.Sarepta Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company earned ($3.42) earnings per share. As a group, sell-side analysts predict that Sarepta Therapeutics will post 3.69 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director directly owned 1,765 shares of the company’s stock, valued at $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently bought and sold shares of SRPT. AQR Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 454.6% in the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after purchasing an additional 6,390,860 shares during the period. First Trust Advisors LP increased its stake in shares of Sarepta Therapeutics by 107.6% in the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock worth $89,995,000 after purchasing an additional 2,143,211 shares during the period. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Sarepta Therapeutics by 183.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock worth $33,627,000 after purchasing an additional 1,129,610 shares during the period. Finally, Erste Asset Management GmbH increased its stake in shares of Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock worth $50,588,000 after purchasing an additional 1,064,530 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.